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The Role of Public-Private Partnerships in Advancing Vaccine 
Technologies and Improving Vaccine Effectiveness and Delivery 
for Developing Countries







PATH is an international nonprofit organization that seeks to improve the 
health of people around the world by advancing technologies, strengthening 

















PATH has 1,100 employees 


















Use of Funds by Area of Focus
Includes vaccine 
PATH programs in vaccines, vaccine technologies, and immunization account for 






Vaccines for Developing Countries
• To be broadly and effectively used in developing countries, vaccine 
products should be: 
 Affordable.
 Optimized for the intended conditions of distribution, storage, and use.
 Acceptable to recipients.
 Easily and safely prepared and delivered. 
• Vaccine product attributes needed for developing-country markets may 
be quite different from those for developed-country markets.
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• Vaccine technologies can help achieve product attributes needed in 
developing-country settings:
 Adjuvants and vaccine delivery technologies can significantly reduce 
the dose and, therefore, the cost of vaccines. 
 Delivery technologies can improve safety and ease of use.
Key Drivers
 Formulation and processing technologies can improve vaccine 
thermostability, minimizing vaccine wastage and allowing use of 
vaccines with greater independence from the cold chain. 
• Various government agencies and philanthropic foundations have 
recognized the important role vaccine technologies can play in creating 
vaccine products that meet developing-country needs.  
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• This presentation will provide an overview of:
 Collaborative public-private partnerships created with funding from 
government agencies and foundations to advance vaccine technologies.
 Examples of technical advancements achieved by public-private 
partnerships.
Presentation Outline
 Common elements of projects.
 Global access considerations.
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Why Public-Private Partnerships?
• Public-private partnerships can bring together entities with expertise in 
specific technologies, biological testing, product development, global 
public health policy, and regulatory affairs to enhance the relevance 
and success of research and development.
• Combining existing, complementary areas of expertise can shorten 
timelines and reduce development risk.
• Partnerships are particularly important when traditional corporate 











Hilleman Laboratories Merck; Wellcome 
Trust 
$130 million Sept. 
2009 
Medicine in Need 
(MEND) 
Develop affordable vaccines for low-income 
countries.  Currently working to develop 
thermostable rotavirus vaccine. 
 MEND Bill & Melinda 
Gates Found-
ation (BMGF) 
$3 million Feb. 
2010 
Sanaria Stabilize Sanaria’s PfSPZ malaria vaccine to 
simplify manufacturing, transportation, and 
storage. 
PATH BMGF $13.6 million Sept. 
2003 
Aktiv-Dry; Arecor; 
Aridis; Crucell; IIL; 
Niro; U. Col.; 
Wuhan; etc. (more 
than 30 
collaborators) 
Evaluate the technical and commercial feasibility 
of applying stabilization methods to vaccines used 
in developing country immunization programs. 
Heat and freeze stabilization with both EPI and 
new vaccines. Hep B, DTP, Hib, measles 
vaccines. 
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PATH BARDA $9.4 million July 
2010 
Aridis; Arecor; U. 
Kansas; Tulane U. 
Test multiple technologies to increase shelf life of 
subunit and live-attenuated influenza vaccines to 
facilitate stockpiling and use. 
Sabin Vaccine Institute BMGF $13.8 million Sept. 
2006 
GWU; U. Kansas; 
Baylor; Butantan 
Inst. 
Research and development of bivalent hookworm 
vaccine, including research on antigen 
stabilization. 
Soligenix, Inc. NIAID $9.4 million Nov. 
2009 
U. Colorado; U. 
Kansas; Tulane 
U.; Battelle. 
Consortium funded to develop thermostable 
technology to advance RiVax
TM
 (ricin toxin 
vaccine) and other rapidly-acting vaccines. 
Stabilitech DTRA $4 million Aug. 
2010 
 Stabilization of biodefense adenovirus-vectored 
and adjuvanted vaccines.   
TransForm 
Pharmaceuticals 




 Design, build, and validate a high-throughput 
formulation platform, apply to improving stability of 
measles vaccine strains. 
 
Note: list not comprehensive.
Vaccine Stabilization Advancements
• Protection from freeze damage:  Formulation approaches developed that 
protect alum-adjuvanted vaccines from damage due to accidental freezing.1 
PATH , U. Colorado; BMGF funding.
• Stabilization of recombinant hookworm vaccine: Na-GST-1 antigen is stable 
up to 6 months at 25°C (control: 3 months at 2°–8°C).2 Sabin Inst., GWU, U. 
Kansas, Baylor U.; BMGF funding.
• Stabilization of influenza vaccines: 
 Spray-dried and freeze-dried subunit influenza vaccine formulations have > 4 
months stability at 37°C (control: 1 week at 37°C). 3 PATH; BARDA funding.
 Foam-dried live attenuated vaccine formulation have > 4 months stability at 37°C 
(control: 1 week at 37°C). 4  PATH, Aridis; BARDA funding.
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1Braun LJ, Tyagi A, Perkins S, et al. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine. 
2008;27:72-79.
2Plieskatt J, Rezende W, Olsen C, et al. Advances in vaccines against neglected tropical diseases: Enhancing physical stability of a 
recombinant hookworm vaccine through biophysical and formulation studies. Human Vaccines & Immunotherapeutics. 2012;8(6):1-12.
3.4 PATH and Aridis Pharmaceuticals, unpublished data, 2012.
Vaccine Adjuvant Projects




Project Partners Comments 
DynaVax NIAID $17 million Sept. 
2008 
 Advance TLR9-acting adjuvants. 
Emory University BMGF 
 





Explore molecular pathways by which adjuvants 
enhance cellular immune responses, comparing 








U. Wash.; ISB; 
Emory U.; 
OHSU.; NYU 
Research consortium funded to develop vaccine 









Develop adjuvants suitable for use with malaria 
vaccine candidates. 
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IDRI BARDA $8.5 million July 
2010 
 Develop and evaluate adjuvant formulations to 
enhance influenza vaccine immunogenicity. 
U. of Lausanne EC $0.7 million Jan. 
2010 
 Vaccine Formulation Laboratory funded to 
facilitate access to adjuvant systems and 
associated know-how for the public sector. 
U. of Lausanne  BARDA $3.1 million Sept. 
2010; 
2011 
 Develop adjuvants and other technologies for 
influenza vaccines that can be transferred without 
the restriction of intellectual property rights. 





Facilitate global access to new adjuvants and 
formulation technologies.  Initial focus: evaluating 
novel adjuvants for potential use in developing an 
affordable inactivated polio vaccine.   
Various Contractors NIAID $60 million Oct. 
2009 
 Multiple contracts awarded for vaccine adjuvant 
discovery and characterization: Mt. Sinai; GSK; 
UCSD; U. Kansas; U. Mich.; & U. Washington. 
 
Vaccine Adjuvant Advancements
• Malaria vaccine development: Preclinical studies showed potent immune 
responses to CelTOS – GLA-SE in small animals, resulting in a protective 
immune response during the infectious mosquito-stage of malaria 
parasites. USAID funding development of a malaria vaccine.1  IDRI, Walter 
Reed; funding from BMGF and USAID.
• Virus-mimicking nanoparticles can stimulate long lasting immunity: 
Immunization of mice with synthetic nanoparticles containing antigens 
plus ligands that signal through TLR4 and TLR7 induced synergistic 
increases in antigen-specific, neutralizing antibodies.2 Emory U., Mt. Sinai, Duke 
U., Georgia Tech, U. Georgia; funding from BMGF and NIH.
1 IDRI, USAID Strike New Collaboration for Malaria Vaccine Development,  Aug.  16, 2011.  Available at: www.idri.org.
2 Kasturi SP, Skountzou I, Albrecht, RA, et al. Programming the magnitude and persistence of antibody responses with innate 
immunity. Nature. 2011; 470:543–547.
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Vaccine Delivery Technology Projects

















Development of inhalable aerosol measles 
vaccine. 
Emory University 





Cardiff U. Development of microneedle technology for 
delivery of influenza vaccines. 
Georgia Tech NIH $10 million Nov. 
2010 
Emory U.; PATH Advance microneedle technology for self-
administration of influenza vaccines through 
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Phase I clinical testing. 




 Advance development of a low-cost, non-
invasive surface electroporation delivery 
device and test its utility in combination with 
synthetic DNA vaccines, including pandemic 
influenza. 




Pharmajet Development of a needle-free Dengue 
vaccine. 












To advance the field of disposable-syringe jet 
injectors for mass immunizations. 
 
Note: list not comprehensive.
Vaccine Delivery Technology Advancements
• Needle-free, intradermal delivery of poliovirus vaccine: Fractional doses (20% 
of full dose) of inactivated polio vaccine given intradermally with a needle-free 
jet injector gave similar levels of seroconversion in infants as full doses given 
intramuscularly.1  Oman Ministry of Health, WHO, CDC, Bioject; funding from BMGF (via PATH) & 
WHO. 
• Microneedle delivery of influenza vaccine: Microneedle delivery of H1N1 virus 
gave similar IgG titers and protection against lethal virus challenge in an animal 
model compared to subcutaneous injection. Protective immunity was longer 
lived with microneedle than subcutaneous administration.2  Emory U., Georgia Tech., 
funding from NIAID.
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1Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. The New England Journal of 
Medicine. 2010;362(25):2351-2359.
2Koutsonanos DG, del Pilar Martin M, Zamitsyn VG, et al. Serological memory and long-term protection to novel H1N1 influenza virus after 
skin vaccination. Journal of Infectious Diseases. 2011;204:582-591.
Bioject (Biojector ® 2000 needle-free device) Georgia Institute of Technology
Common Features of Projects
• Vaccine targets are typically diseases of global impact: HIV, malaria, 
influenza, tuberculosis, polio, dengue, measles.
• Many projects involve robust partnerships among nonprofit organizations, 
private-sector technology and vaccine companies, and universities.  Private 
sector, commercial partners may be involved from project inception, or 
may join later.
• Funding often supports work to a proof-of-concept stage.  Additional 
funding is needed for full product development.
• Funding (especially from foundations) comes with certain requirements 
relating to global access to data and any resulting products.   
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Global Access to Data
• Publication of findings and access to project data promote:
 Innovation—encouraging diversity of analysis and opinion and facilitating synthesis 
of results from individual projects into a larger whole.
 Collaboration—between teams and institutions.
 Efficiency—preventing unnecessary duplication of effort.
 Accountability—by encouraging independent verification and analysis.
 Capacity strengthening—facilitating education of new researchers and evaluators. 1
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1Global Health Data Access Principles. Bill & Melinda Gates Foundation. Available at: www.gatesfoundation.org. 
Global Access to Products
• Funding provided directly by funders or via primary grantees may be used to 
develop products by private-sector collaborators. Agreements should 
consider:
 Availability—is the program sufficiently rigorous, funded, and prioritized 
to provide a reasonable opportunity for success?  Is the private-sector 
company’s need for commercial benefit recognized in a way that will 
ensure a sustainable commitment?
 Accessibility—will sufficient quantities of the resulting product be 
available to meet public-sector demand in developing countries?
 Affordability—has pricing been agreed upon that can result in widespread 
adoption in public-sector programs of developing countries?1
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1PATH’s Guiding Principles for Private-Sector Collaborations. PATH. Available at: www.path.org.
Conclusions
• Over the past 10 years, public-private partnerships funded by government 
agencies and foundations have significantly advanced vaccine 
technologies that can address specific developing-country needs.
• Additional support by industry, funders, and regulatory agencies will be 
needed to ensure the incorporation of new technologies into vaccine 
products that meet developing-country needs.
• Vaccine formulation, delivery, and packaging technologies need to be 
incorporated early in the product development process.
• Global access requirements of private-sector partners are an appropriate 
quid pro quo for the funding provided and are typically structured to allow 
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